Reilly Financial Advisors’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Reilly Financial Advisors’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-100	Closed	-$1K	–	993
2016 Q4	$1K	Hold	100	–	–	﹤0.01%	826
2016 Q3	$1K	Hold	100	–	–	﹤0.01%	825
2016 Q2	$1K	Hold	100	–	–	﹤0.01%	792
2016 Q1	$1K	Hold	100	–	–	﹤0.01%	1156
2015 Q4	$2K	Hold	100	–	–	﹤0.01%	1101
2015 Q3	$2K	Hold	100	–	–	﹤0.01%	1162
2015 Q2	$2K	Hold	100	–	–	﹤0.01%	1257
2015 Q1	$3K	Hold	100	–	–	﹤0.01%	1133
2014 Q4	$2K	Buy	+100	New	+$2.05K	﹤0.01%	783

Other funds holding OMED

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ASP

Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Reilly Financial Advisors's OMED Position: Q1 2017 in Review

Reilly Financial Advisors sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q1 2017, closing a stake of 100 shares — an estimated $1K sold.

Reilly Financial Advisors first reported a position in OMED in Q4 2014 and held it in 9 quarters. The position peaked at $3K in Q1 2015. 85 funds tracked by Wall St. Rank hold OMED as of Q1 2017.

Reilly Financial Advisors reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
Reilly Financial Advisors sold 100 OncoMed Pharmaceuticals, Inc. shares in Q1 2017, an estimated $1K.
Reilly Financial Advisors first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2014 and held it in 9 quarters.
Reilly Financial Advisors's OncoMed Pharmaceuticals, Inc. position peaked at $3K in Q1 2015.
85 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q1 2017.

Based on Reilly Financial Advisors's 13F filing for Q1 2017, filed 18 Apr 2017.